The Infectious Diseases Society of America (IDSA) recently revised its recommendations for adult hospital patients with two common types of hospital-acquired infections to receive a shorter 7-day course of antibiotics rather than the previously recommended 8 to 15 days. This important change mitigates a patient’s exposure to antibiotic-related side effects, reduces the risk of antibiotic resistance, condenses length of stay and decreases overall costs…without reducing the benefits of therapy. EvidenceCare, a bedside, decision-support tool for providers, has fully integrated the new IDSA guidelines into its comprehensive Pneumonia pathway authored by Dr. Frank LoVecchio, co-Medical Director of the Banner Regional Control Center and Vice Chairman of Emergency Medicine for Maricopa Medical Center in Phoenix, Arizona.
In a news release by the IDSA, the change was intended to “ensure safe and effective treatment while limiting the development of antibiotic resistance.” As part of this guideline revision, the IDSA also updated their Ventilator-Associated Pneumonia (VAP) treatment recommendations to emphasize the empiric treatment of multi-drug resistant organisms (MDROs) such as MRSA and Pseudomonas in patients who are at risk or in institutions that have high rates of infection with these organisms.
Hospital-acquired pneumonia occurs in 5-15% per 1,000 hospital admissions and accounts for approximately 15% of all hospital-acquired infections (HAC). It has been shown to increase a patient’s hospital stay by an average of 7 to 9 days with an associated cost of more than $40,000 per patient. According to the IDSA, it can cause serious complications such as respiratory failure, septic shock, kidney failure and can be fatal 10-15% of the time.
“As an Emergency Physician, I want to know that the resources I am incorporating into my care decisions are evidence-based and as current as possible,” noted EvidenceCare founder, Dr. Brian Fengler. “Our goal is to help providers deliver the best care possible to their patients, improve antibiotic stewardship, and reduce costly provider variability.”
With a reputation for delivering the most current guidelines, EvidenceCare incorporated and deployed the revised IDSA guidelines for its users around the world as soon as they became available. Easy access to current decision support is a stalwart of EvidenceCare’s content delivery system. The company offers providers free access to pathways that account for more than 80% of the most common conditions presented within a hospital’s Emergency Department. The company’s website is www.evidence.care.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161014005373/en/Business Wire
Last updated on: 14/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.